Mathew Raeba, Murugavel Boopathy
Ophthalmology, Canadian Specialist Hospital, Dubai, ARE.
Ophthalmology, Aster Hospital, Al Qusais, Dubai, ARE.
Cureus. 2024 Aug 7;16(8):e66405. doi: 10.7759/cureus.66405. eCollection 2024 Aug.
Vogt-Koyanagi-Harada (VKH) disease is a multisystem inflammatory disease that usually presents with bilateral panuveitis. Unilateral manifestations of VKH, albeit rare, have been described. Choroidal neovascularization may occur as a complication during the disease. Reactivation of uveitis may also occur during treatment. A patient with unilateral features of VKH disease presented with two distinct types of choroidal neovascular membranes and two episodes of reactivation of posterior uveitis. He underwent treatment with a combination of systemic steroids/immunosuppressive agents, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, and dexamethasone implants with good clinical response. Patients with VKH disease need to be diagnosed early, treated adequately with a combination of systemic and ocular medication, and followed up diligently for any complication that may arise, to optimize visual acuity.
伏格特-小柳-原田(VKH)病是一种多系统炎症性疾病,通常表现为双侧全葡萄膜炎。VKH的单侧表现虽然罕见,但也有相关描述。脉络膜新生血管可能作为该病的一种并发症出现。在治疗期间也可能发生葡萄膜炎复发。一名具有VKH病单侧特征的患者出现了两种不同类型的脉络膜新生血管膜以及两次后葡萄膜炎复发。他接受了全身类固醇/免疫抑制剂、玻璃体内抗血管内皮生长因子(抗VEGF)药物以及地塞米松植入物联合治疗,临床反应良好。VKH病患者需要早期诊断,采用全身和眼部药物联合进行充分治疗,并对可能出现的任何并发症进行密切随访,以优化视力。